Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person20
ONCOLYTICS BIOTECH INC
Company
NKGen Biotech, Inc.
Company
Edesa Biotech, Inc.
Company
Krystal Biotech, Inc.
Company
XBiotech Inc.
Company
Fortress Biotech, Inc.
Company
Moleculin Biotech, Inc.
Company
PharmaCyte Biotech, Inc.
Company
GOLDENWELL BIOTECH, INC.
Company
Vir Biotechnology, Inc.
Company
Oncotelic Therapeutics, Inc.
Company
MAIA Biotechnology, Inc.
Company
PUMA BIOTECHNOLOGY, INC.
Company
Sana Biotechnology, Inc.
Company
BridgeBio Oncology Therapeutics, Inc.
Company
Cardlytics, Inc.
Company
Bolt Biotherapeutics, Inc.
Company
SAB Biotherapeutics, Inc.
Company
CG Oncology, Inc.
Company
Beta Bionics, Inc.
Company
Primary record10
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On November 4, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing translational data from its study in squamous cell anal cancer patients, specifically pelareorep's a
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On October 27, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing updated data from Cohort 4 of the GOBLET study, which is evaluating pelareorep and atezolizumab in s
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On October 20, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing the details for a REO 033 trial-in-progress abstract and e-poster that will be presented at the Euro
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On October 14, 2026, Oncolytics Biotech Inc. (the Company ) issued a press release announcing it is expecting to receive the final grant payment from the Pancreatic Cancer Action Network later th
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On October 12, 2026, Oncolytics Biotech Inc. (the Company ) issued a press release announcing certain updates relating to its intellectual property portfolio and ongoing efforts to extend patent
ONCOLYTICS BIOTECH INC filed DEF 14A
SEC form DEF 14A filed by ONCOLYTICS BIOTECH INC (CIK 1129928) on 2026-10-06.
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On September 29, 2026, Oncolytics Biotech Inc. (the Company ) issued a press release discussing pelareorep's ability to change the tumor microenvironment from immunologically inactive to active i
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On September 28, 2026, Oncolytics Biotech Inc. (the Company ) issued a press release announcing certain updates and progress relating to the REO 033 colorectal cancer study. The information set f
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On September 10, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing results from a preclinical study evaluating pelareorep in combination with a pan-RAS inhibitor in
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On August 18, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing feedback from the U.S. Food and Drug Administration related to the planned pivotal Part B expansion o